PharmaCyte Biotech(PMCB) - 2023 Q1 - Quarterly Report

Company Focus and Product Development - The company is focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its proprietary "Cell-in-a-Box" technology [133]. - The current product candidate, "CypCaps™," is designed to encapsulate genetically engineered live human cells for therapeutic applications [133]. - The company is exploring therapies for Type 1 diabetes using encapsulated insulin-producing cells as a bio-artificial pancreas [137]. - The company is also developing therapies for malignant ascites using encapsulated cells administered in the peritoneal cavity [136]. Regulatory and Clinical Trials - Due to a clinical hold placed by the FDA on the IND for a planned trial in LAPC, the company is facing delays and increased costs in its development efforts [129]. - The FDA has requested additional studies and data to lift the clinical hold, including stability studies and compatibility assessments of delivery devices [142]. - The company is currently conducting 10 biocompatibility studies requested by the FDA, with 8 completed successfully [146]. - A pig study has commenced to evaluate biocompatibility and long-term implantation of CypCaps™, with the first phase completed and preliminary data being evaluated [150]. - The company is facing potential delays in clinical trials due to COVID-19, impacting patient enrollment and site activation [149]. Financial Performance - The company reported no revenues for the three months ended July 31, 2022, consistent with the same period in 2021 [157]. - Total operating expenses increased by $657,257 to $1,680,608 for the three months ended July 31, 2022, compared to $1,023,351 in the same period in 2021 [158]. - Research and Development (R&D) expenses rose to $159,273, an increase of 11% from $143,613 in the prior year [159]. - Compensation expenses increased by 22% to $327,718 from $268,885 in the previous year [159]. - General and administrative, legal, and professional expenses surged by 108% to $1,140,890, up from $547,694 in the same period last year [159]. - Loss from operations increased by $657,257 to $1,680,608 for the three months ended July 31, 2022, primarily due to increased R&D and legal expenses [160]. - Other income for the three months ended July 31, 2022, was $135,596, compared to a net expense of $2,067 in the same period in 2021, driven by interest income of $139,502 [161]. Cash Flow and Funding - Net cash used in operating activities for the three months ended July 31, 2022, was $1,084,378, a decrease from $1,241,221 in the same period of 2021 [163]. - Cash and cash equivalents as of July 31, 2022, totaled approximately $82.2 million, up from approximately $959,000 as of July 31, 2021 [166]. - Working capital increased to approximately $81.2 million as of July 31, 2022, compared to approximately $583,000 as of July 31, 2021 [166]. - Cash used in financing activities for the three months ended July 31, 2022, was $2,089,967, primarily due to the repurchase of common stock [165]. - The company raised approximately $70 million from the Second Offering, which included shares of common stock and warrants [169]. - Total funding of approximately $87.4 million was provided by investors through the First Offering, Second Offering, and Warrant Exercises to support operations and R&D [170]. - The company reported a decrease in cash of $3,173,041 for the three months ended July 31, 2022, compared to a decrease of $1,242,836 in the same period of 2021 [163]. - The company had no investing activities for the three months ended July 31, 2022, and 2021 [164]. Intellectual Property and Business Strategy - The expiration of patents covering the Cell-in-a-Box technology raises concerns about the company's ability to protect its intellectual property [131]. - The company has entered a Cooperation Agreement with Iroquois Master Fund Ltd. to reconstitute its Board of Directors and review its business strategy [133]. - The company is under review by its Business Review Committee regarding spending on programs dependent on SG Austria and Austrianova [171]. - The total estimated cost for service agreements related to the clinical hold on the IND submission involving LAPC is approximately $373,000 [173].